Drug Profile
Research programme: cell and gene therapies - Athenex/Baylor College of Medicine
Alternative Names: CAR-modified NKT cell therapy; CMD 504; CMD 601; Off-the-shelf allogeneic cell therapy; Off-the-shelf allogeneic NKTLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Baylor College of Medicine
- Developer Athenex
- Class Gene therapies; NKT cell therapies; T lymphocyte cell therapies
- Mechanism of Action Gene transference; Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 04 May 2021 Kuur Therapeutics has been acquired by Athenex